drugset / Trial / NCT04697641
Helicobacter Pylori Eradication in Functional Dyspepsia
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to study benefit of eradicating Helicobacter Pylori in patients with functional dyspepsia as compared to symptomatic treatment only. Helicobacter pylori positive patients with Functional Dyspepsia will be divided into two study groups, one will receive Helicobacter pylori eradication therapy and other will receive symptomatic treatment. Symptom relief based on Likert scale will be compared in both groups.
Timeline
- Start
- 2017-09-01
- Primary completion
- 2019-05-31
- Completion
- 2019-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1000 mg | — |
| Subject | Clarithromycin | Small molecule | 500 mg | — |
| Comparator | Acotiamide | Small molecule | 100 mg | — |
| Comparator | Itopride | Small molecule | 50 mg | — |
| Comparator | Levosulpiride | Small molecule | 25 mg | — |
| Background | Pantoprazole | Other / unclassified | 40 mg | — |